Genetic Variations Associated with Long-Term Treatment Response in Bipolar Depression.
ATP Binding Cassette Transporter, Subfamily B
/ genetics
Adult
Age of Onset
Antidepressive Agents
/ administration & dosage
Biomarkers, Pharmacological
Bipolar Disorder
/ drug therapy
Cytochrome P-450 CYP3A
/ genetics
Female
Genetic Variation
/ genetics
Humans
Male
Middle Aged
Pharmacogenetics
Precision Medicine
Selective Serotonin Reuptake Inhibitors
/ administration & dosage
TOR Serine-Threonine Kinases
/ genetics
bipolar disorder
genetic variants
pharmacogenetics
precision medicine
psychiatric disorders
treatment response
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
18 08 2021
18 08 2021
Historique:
received:
07
07
2021
revised:
09
08
2021
accepted:
16
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
4
2
2022
Statut:
epublish
Résumé
Several pharmacogenetic-based decision support tools for psychoactive medication selection are available. However, the scientific evidence of the gene-drug pairs analyzed is mainly based on pharmacogenetic studies in patients with major depression or schizophrenia, and their clinical utility is mostly assessed in major depression. This study aimed at evaluating the impact of individual genes, with pharmacogenetic relevance in other psychiatric conditions, in the response to treatment in bipolar depression. Seventy-six patients diagnosed with bipolar disorder and an index major depressive episode were included in an observational retrospective study. Sociodemographic and clinical data were collected, and all patients were genotyped using a commercial multigene pharmacogenomic-based tool (Neuropharmagen
Identifiants
pubmed: 34440433
pii: genes12081259
doi: 10.3390/genes12081259
pmc: PMC8391230
pii:
doi:
Substances chimiques
ABCB1 protein, human
0
ATP Binding Cassette Transporter, Subfamily B
0
Antidepressive Agents
0
Biomarkers, Pharmacological
0
Serotonin Uptake Inhibitors
0
Cytochrome P-450 CYP3A
EC 1.14.14.1
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Pharmacogenet Genomics. 2011 Mar;21(3):152-61
pubmed: 20216335
F1000 Biol Rep. 2009 Mar 24;1:23
pubmed: 20948663
J Toxicol Sci. 2013;38(3):349-54
pubmed: 23665933
Actas Esp Psiquiatr. 2002 Sep-Oct;30(5):301-4
pubmed: 12372226
Curr Opin Psychiatry. 2014 Jan;27(1):43-51
pubmed: 24270480
Epilepsia. 2014 Apr;55(4):496-506
pubmed: 24597466
Pharmacogenomics. 2013 Jan;14(1):47-62
pubmed: 23252948
Eur J Clin Pharmacol. 2006 Dec;62(12):1049-53
pubmed: 17089108
J Psychiatr Res. 1988;22(1):21-8
pubmed: 3397906
Bipolar Disord. 2018 Mar;20(2):97-170
pubmed: 29536616
N Engl J Med. 2020 Jul 2;383(1):58-66
pubmed: 32609982
Clin Pract Epidemiol Ment Health. 2007 Jun 07;3:5
pubmed: 17555558
N Engl J Med. 2011 Mar 24;364(12):1134-43
pubmed: 21428769
Eur Neuropsychopharmacol. 2021 Jun;47:31-33
pubmed: 33895615
Pharmacogenet Genomics. 2006 Apr;16(4):297-306
pubmed: 16538176
World J Biol Psychiatry. 2013 Apr;14(3):154-219
pubmed: 23480132
Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):469-480
pubmed: 30466219
Pharmacogenomics J. 2016 Apr;16(2):202-8
pubmed: 25987242
Lancet. 2016 Apr 9;387(10027):1561-1572
pubmed: 26388529
Pharmacogenomics. 2016 Dec;17(18):2039-2069
pubmed: 27918249
J Affect Disord. 2011 Oct;133(3):443-9
pubmed: 21620480
Clin Pharmacol Ther. 2018 Apr;103(4):574-581
pubmed: 29392710
J Psychopharmacol. 2016 Jun;30(6):495-553
pubmed: 26979387
Eur Neuropsychopharmacol. 2020 Jun;35:49-60
pubmed: 32409261
Pharmgenomics Pers Med. 2018 Mar 16;11:35-42
pubmed: 29588611
J Psychiatr Res. 2016 Feb;73:86-95
pubmed: 26704739
Eur Neuropsychopharmacol. 2019 Nov;29(11):1199-1212
pubmed: 31590972
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
J Clin Psychopharmacol. 2014 Apr;34(2):256-60
pubmed: 24525658
Pharmaceutics. 2019 Sep 02;11(9):
pubmed: 31480800
Arch Gen Psychiatry. 2011 Mar;68(3):241-51
pubmed: 21383262
Mol Psychiatry. 2011 Dec;16(12):1234-46
pubmed: 20938433
Neuron. 2008 Jan 24;57(2):203-9
pubmed: 18215618
BMC Psychiatry. 2017 Jul 14;17(1):250
pubmed: 28705252
Nat Genet. 2019 May;51(5):793-803
pubmed: 31043756
Br J Pharmacol. 2012 Jan;165(2):289-312
pubmed: 21718296
JAMA. 2018 Mar 27;319(12):1197-1198
pubmed: 29507950
J Pers Med. 2019 Apr 30;9(2):
pubmed: 31052247
Eur Neuropsychopharmacol. 2015 Jan;25(1):51-9
pubmed: 25499605
BMJ Open. 2014 Mar 04;4(3):e004216
pubmed: 24595134
Pharmacogenomics. 2017 Oct;18(15):1459-1467
pubmed: 28975860
Biol Psychiatry. 2013 Apr 1;73(7):679-82
pubmed: 23237317
Pharmacogenomics J. 2015 Aug;15(4):332-9
pubmed: 25487678
Int J Bipolar Disord. 2020 Jul 4;8(1):23
pubmed: 32632502
Bone Joint Res. 2015 Sep;4(9):152-3
pubmed: 26392591
Pharmacogenomics. 2020 Jun;21(8):559-569
pubmed: 32301649
Int J Neuropsychopharmacol. 2017 Feb 1;20(2):121-179
pubmed: 27816941
Lancet. 2020 Dec 5;396(10265):1841-1856
pubmed: 33278937
Lancet. 2016 Mar 12;387(10023):1085-1093
pubmed: 26806518
Mol Diagn Ther. 2018 Aug;22(4):409-420
pubmed: 29790107
Nature. 2004 Apr 1;428(6982):486
pubmed: 15057820
Psychiatry Investig. 2019 Sep;16(9):645-653
pubmed: 31455064
Pharmaceutics. 2019 Dec 21;12(1):
pubmed: 31877761